## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Fraser et al.

Application Number: to be assigned

Group Art Unit: to be assigned

Filed: herewith

Examiner: to be assigned

Title: Borrelia Burgdorferi Polynucleotides and

Sequences

Attny. Docket No. PB370US

#10 Plunketh

## INFORMATION DISCLOSURE STATEMENT **PURSUANT TO 37 C.F.R. § 1.56**

**Assistant Commissioner for Patents** Washington, D.C. 20231

SIR:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorneys for Applicants hereby direct the Examiner's attention to references AA-AB listed on the attached form PTO/SB/08A. Copies of references AA-AB are enclosed.

Identification of the listed references is not to be construed an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

The above information is presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 CFR 1.104(a) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be considered during the prosecution of this application.

Applicants respectfully request that the Examiner review the listed reference and that the reference be made of record in the file history of the application.

Jc18 Rec'd PCT/PTO 2 4 APR 2001

Pursuant to 37 C.F.R. § 1.97(b), since this information disclosure statement is being filed before the mailing date of a first Office Action on the merits, no fee is due in connection herewith. However, should the Patent Office determine otherwise, please charge the required fee to Human Genome Sciences, Inc., deposit account no. 08-3425. A copy of this sheet is enclosed.

Respectfully submitted,

Date: Cepyl 24, 2001

Kenley K Hoover Attorney for Applicants (Reg. No. 40,302)

Human Genome Sciences, Inc.

9410 Key West Avenue Rockville, MD 20850 (301) 610-5771 (phone)

KKH/ur

Please type a plus sign (+) inside this box

+

PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute f	or form 1449/PTO			Complete if Known		
IN	FORMATION:	DISCLO	SURE	Application Number	Unassigned	
ST	ATEMENT BY	APPLIC	CANT	Filing Date	April 24, 2001	
			C2 11 V 1	First Named Inventor	Fraser, et al.	
	(		`	Group Art Unit	Unassigned	
	(use as many sheet	s as necessa	ary)	Examiner Name	Unassigned	
Sheet	1	of	1	Attorney Docket Number	PB370US	

						U.S. PATENT DOCUMENTS		
Examiner Initials	Cite No. 1	U.S. Patent Document				N. CD.	Date of Publication	Pages, Columns, Lines,
		Code <sup>2</sup>	Number	Kii (if kn		Name of Patentee or Applicant of Cited Document	of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear

				F	OREIGN PATENT DOCUMENT	rs		
Examiner Initials	Cite No. 1			Kind Code <sup>5</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Tre
								Ī
								H
								T

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS							
Examiner Initials	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	r				
		Barbour et al., The nucleotide sequence of a linear plasmid of Borrelia burgdorferi reveals similarities to, J. of Bacteriol., 178(22):6635-6639 (1996)	Ī				
	AB	Fraser et al., Genomic Sequence of a Lyme disease spirochaete, Borrelia burgdorferi, Nature, 390:580-586 (11 December 1997)	Ī				
	···········		F				
			$\vdash$				

_			
Examiner	Da	nto	
G: .	Da	iie	1
Signature	l Co	onsidered	ı

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.